Adenosine A(2A) receptors are a new target for drug development in Parkinson´s disease. Some experimental and clinical data suggest that A(2A) receptor antagonists can provide symptomatic improvement by potentiating the effects of (L)-DOPA as well as a decrease in secondary effects such as (L)-DOPA-induced dyskinesia. (L)-DOPA-induced behavioral sensitization in unilateral 6-hydroxydopamine-lesioned rats is frequently used as an experimental model of (L)-DOPA-induced dyskinesia. In the present work this model was used to evaluate the effect of the A(2A) receptor agonist CGS 21680 and the AA receptor antagonist MSX-3 on (L)-DOPA-induced behavioral sensitization and 6-hydroxydopamine-induced striatal dopamine denervation. (L)-DOPA-induced behavioral sensitization was determined as an increase in (L)-DOPA-induced abnormal involuntary movements and enhancement of apomorphine-induced turning behavior. Striatal dopamine innervation was determined by measuring tyro sine-hydroxylase immunoreactivity. Chronic administration of MSX-3 was not found to be effective at counteracting (L)-DOPA-induced behavioral sensitization. On the other hand, CGS 21680 completely avoided the development of (L)-DOPA-induced behavioral sensitization. The analysis of the striatal dopamine innervation showed that (L)-DOPA-CGS 21680 co-treatment conferred neuroprotection to the toxic effects of 6-hydroxydopamine. This neuroprotective effect was dependent on A(2A) and D-2 receptor stimulation, since it was counteracted by MSX-3 and by the D-2 receptor antagonist haloperidol. These results open new therapeutic avenues in early events in Parkinson´s disease.
Attenzione! Scheda prodotto non ancora validata dall'Ateneo
Dati e metadati della pubblicazione sono in fase di verifica da parte dell'Ateneo. In caso di errori o violazione dei diritti d'autore, contattare: email@example.com
|Anno di pubblicazione:||2004|
|Titolo:||Neuroprotective effect of L-DOPA co-administered with the adenosine A(2A) receptor agonist CGS 21680 in an animal model of Parkinson's disease|
|Autori:||L.F. Agnati; G. Leo; A.V. Vergoni; E. Martinez; J. Hockemeyer; C. Lluis; R. Franco; K. Fuxe; S. Ferre|
|Autori interni:||AGNATI, Luigi Francesco |
VERGONI, Anna Valeria
|Rivista:||BRAIN RESEARCH BULLETIN|
|Appare nelle tipologie:||Articolo su rivista|
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris